

10/576904

Express Mail mailing label number ED 753047410 US
Date of Express Mail deposit: April 21, 2006

Attorney Docket No. AC-04-US

JAP20Rec'd PCT/PTO 21 APR 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bezencon, et al.)	Examiner: TBD
)	
Serial No.: TBD)	Group Art Unit: TBD
)	
(National Stage of PCT/EP2004/011704))	
)	
(Filed concurrently under 35 USC 371))	Attorney Docket: AC-04-US
)	
Title: Novel Diazabicyclononene and Tetra-)	
hydropyridine Derivatives with a New)	
Polar Side-Chain)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In accordance with 37 C.F.R. §1.97 *et. seq.*, Applicant provides the enclosed materials for the Examiner's consideration in connection with the above-identified patent application.

Applicant respectfully requests that this Information Disclosure Statement and the documents listed on the attached Form 1449 and enclosed herewith be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Copies of foreign documents and communication from a foreign patent office are enclosed herein.


The information contained in this Information Disclosure Statement is not to be

~~AP20 Rec'd PTO 21 APR 2006~~

construed as 1) a representation that a search has been conducted; 2) additional information material to the examination of this application does not exist; 3) the information, protocol, results and the like reported by third parties are accurate or enabling; the information is considered to be material to patentability; or 4) that the information constitutes prior art to the current application.

It is believed that no fee is required. If a fee is required, please charge the same to Deposit Account No. 50-3464. The Examiner is invited to contact the Applicant's representative at the telephone number listed below if there are any questions.

Respectfully submitted,



Thomas Hoxie
Reg. No. 32,993

Date: April 21, 2006

HOXIE & TSO LLP
374 Millburn Avenue
Suite 300E
Millburn, New Jersey 07041
973-467-2126

AP20RscdPCTPTO 21 APR 2006

PTO/SB/08A (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	TBD 107576904
		Filing Date	April 21, 2006
		First Named Inventor	BEZENCON, et al.
		Group Art Unit	TBD
		Examiner Name	TBD
Sheet 1 of 1		Attorney Docket No: AC-04-US	

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2003/0013883 A1	01/16/2003	Tamagnan et al.	
	2002/0004513 A1	01/10/2002	Andersson et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	WO 04/002957 A1	01/08/2004	Bezencon et al.		
	WO 04/096803 A1	11/11/2004	Bezencon et al.		
	WO 04/096804 A1	11/11/2004	Bezencon et al.		
	WO 04/096799 A1	11/11/2004	Bezencon et al.		
	WO 04/096366 A1	11/11/2004	Bezencon et al.		
	WO 04/096116 A2	11/11/2004	Bezencon et al.		
	WO 04/096116 A3	11/11/2004	Bezencon et al.		
	WO 04/105762 A1	12/09/2004	Bur et al.		
	WO 03/093267 A1	11/13/2003	Bezencon et al.		
	WO 01/60823 A1	08/23/2001	Cignarella et al.		
	WO 97/09311	03/13/1997	Binggeli et al.		
	WO 92/05174	04/02/1992	King et al.		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MARKI, H.P. et al. <i>Piperidine renin inhibitors: from leads to drug candidates</i> , IL Farmaco, 2001, pages 21-27, Vol. 56.	
		CHEN, Z. et al. <i>Synthesis and Dopamine Transporter Affinity of 2-(Methoxycarbonyl)-9-methyl-3-phenyl-9-azabicyclo[3.3.1]nonane Derivatives</i> , J. Med. Chem., 1996, pages 4744-4749, Vol. 39, No. 24.	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached